ROMY contains romiplostim, a thrombopoietin receptor agonist that stimulates platelet production in the bone marrow.
Recommended for:
The product is administered subcutaneously once weekly. Dosage is individualised based on patient platelet counts and clinical response.
Contraindications:
Side effects: